Chung, Caroline

Coire, Claire

Fat, Mary Jane Lim

Jiang, Haiyan

Karamchandani, Jason

Kiehl, Tim Rasmus

Laperriere, Normand

Mason, Warren P

Mcnamara, Mairead

Millar, Barbara-Ann

Sahebjam, Solmaz

Background Radiotherapy with procarbazine, lomustine and vincristine improves overall survival (OS) in patients with 1p19q codeleted anaplastic oligodendroglioma (AOD)/anaplastic oligoastrocytoma (AOA). This retrospective review investigates outcomes with upfront temozolomide (TMZ) alone in 1p19q codeleted/partially deleted AOD, AOA, oligodendroglioma (OD) or oligoastrocytoma (OA).Methods Patients (pts) with 1p19q codeleted/partially deleted AOD, AOA, OD and OA were analyzed for OS and progression free survival (PFS) using Kaplan-Meier method, and prognostic factors using Cox proportional hazard model.Results A total of 106 pts (Dec 97-Dec 13) were included. Median (med) age was 40 yrs (19-66), 58 (55%) male, performance status (PS) 0 in 80 (75%) pts. 1p19q status was codeleted in 66 (62%), incompletely codeleted in 27 (25%), 1p or 19q loss alone in 4 (4%) and 9 (8%) pts respectively. Upfront treatment was given in 72 (68%) pts; TMZ alone in 52 (49%) was well tolerated with med 12 cycles (1-24). Med time to radiotherapy in 47 pts (44%); 34.7 mo, 41.2 mo in 9 pts with codeleted/incompletely codeleted AOD who received upfront TMZ alone. Med OS was not reached for all groups (med follow up 5.1yrs) [Table]. On multivariable analysis, PS 1 vs 0 (Hazard ratio [HR] 2.78, 95% confidence interval [CI] 1.57-4.93, 

The University of Manchester - Institutional Repository

Temozolomide for 1p19q co-deleted and partially deleted gliomas

Temozolomide for 1p19q co-deleted and partially deleted gliomas

Abstract

Similar works

Full text

Available Versions

The University of Manchester - Institutional Repository